Shionogi and F2G have reported detailed Phase 3 results for investigational oral antifungal olorofim, which was compared with AmBisome followed by standard of care in adults with invasive aspergillosis. Presented at IDWeek on October 22, 2026, the OASIS study met its primary endpoint of non-inferiority for all-cause mortality at Day 42. The findings add clinical evidence for a potential treatment option in a difficult-to-treat patient population, while regulatory review and approval remain necessary before olorofim could be marketed.
The update follows the partners’ June announcement of positive topline results. The newly reported data provide more detail on mortality, global response, adverse events and hospital discharge. They also sharpen the commercial question: whether an oral option with a different safety and administration profile could address a gap for patients who cannot use azole antifungals.
What did the OASIS Phase 3 trial find?
OASIS was a global, randomized Phase 3 study involving 225 adults with invasive aspergillosis whose infection was refractory to, or for whom azole therapy was inappropriate. Participants received either olorofim or AmBisome followed by standard of care. The primary endpoint was all-cause mortality at Day 42.
The Day 42 mortality rate was 23.8% in the olorofim group (36 of 151 patients) and 24.3% in the AmBisome-plus-standard-care group (18 of 74). The reported difference was -0.5 percentage points, with a 95% confidence interval of -13.1 to 10.8%. The trial met its prespecified non-inferiority criterion. This means the study supported olorofim as not unacceptably worse than the comparator under the trial’s statistical design; it did not demonstrate that olorofim was superior.
That distinction matters. Non-inferiority results can support a regulatory submission, but they do not establish that the new treatment improves survival compared with existing care. The study’s results need to be assessed alongside the endpoint design, safety data, and the needs of the specific patient group.
Five findings that stand out
1. Day 42 mortality was similar between the treatment groups.
The mortality results were close: 23.8% with olorofim and 24.3% with AmBisome followed by standard care. The primary endpoint supports further regulatory review for the patient population studied.
2. Global response rates were similar at Day 84.
An independent data review committee recorded a global response at Day 84 in 30.5% of patients receiving olorofim and 28.4% receiving AmBisome plus standard care. At Day 42, the respective rates were 26.5% and 31.1%. The study defined successful global response using clinical, radiological and mycological components.
3. Drug-related adverse events were reported less often with olorofim.
At least one drug-related adverse event was reported in 35.8% of the olorofim group, compared with 63.9% of the comparator group. The partners attributed much of the difference to renal adverse events, reported in 1.3% and 22.2% of patients, respectively. These are study findings, not a guarantee of an individual patient’s response or risk.
4. Liver safety remains an area to monitor.
Drug-induced liver injury events assessed as at least possibly related to study treatment were reported at similar rates: 4.6% with olorofim and 4.2% with AmBisome plus standard care. The partners identified liver injury as an important safety signal for olorofim and other antifungal agents, so this issue will remain relevant in regulatory and clinical assessment.
5. Patients in the olorofim arm were discharged earlier on average.
The reported mean hospital stay was 17 days for patients receiving olorofim and 28 days for those receiving AmBisome plus standard care. This could be a relevant health-system outcome if supported by further review, but it should not be read as proof that olorofim alone caused the difference.
Why the oral formulation and target population matter
Invasive aspergillosis is a serious fungal infection that primarily affects immunocompromised patients. Treatment can be challenging when patients cannot take available azole antifungals because their infection is refractory or the therapy is unsuitable. The OASIS trial focused on this population rather than on all patients with aspergillosis.
Olorofim belongs to the orotomide class and is being developed as an oral antifungal with a novel mechanism of action. An oral treatment could offer a different administration option from an intravenous regimen, but its role in practice will depend on the full clinical evidence, regulatory decisions, prescribing information and local treatment guidelines.
The commercial opportunity will therefore depend on more than the Phase 3 endpoint. Physicians and health systems will need to understand which patients are eligible, how efficacy and safety compare with available options, and how the treatment fits into hospital protocols and reimbursement systems.
What happens next in the United States and Japan?
F2G anticipates resubmitting a New Drug Application to the U.S. Food and Drug Administration by the end of 2026. Shionogi is responsible for regulatory submissions in Europe and Asia, including Japan, according to the partners’ announcement. Olorofim remains investigational; the Phase 3 results do not mean the drug is approved or available for sale.
For the U.S. market, the key upcoming milestone is the FDA’s review of the application and supporting evidence. In Japan, Shionogi’s regional role makes the submission pathway and local evaluation important developments to follow. Any launch timing will depend on regulatory review and decisions in each market.
Best-fit Report
Recommended report: Invasive Fungal Infection Treatment Market
This is the closest fit because its scope specifically includes invasive aspergillosis, antifungal drug classes, distribution channels and regional markets, including the United States and Japan. DataM Intelligence lists the report as updated on October 1, 2026, making it a relevant companion for readers assessing how olorofim’s clinical progress fits into the wider treatment landscape.